Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Ardelyx - What They Never Told You

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

2 Overlooked Stocks to Snap Up in 2025

2 Overlooked Stocks to Snap Up in 2025

While much of Wall Street’s attention in 2025 centers around AI names, two under-the-radar companies are quietly getting stronger.

Is This Under-$10 Stock the Next Big Biotech Winner?

Is This Under-$10 Stock the Next Big Biotech Winner?

This could be the next multibagger hiding in biotech under $10.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Small-Cap Stock Could 10x by 2030, But It’s Not for the Faint of Heart

Ardelyx could be one of the most overlooked small-cap stories of the decade.

2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential

The risk is high in small-cap growth stocks, but the reward can be transformative.

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Why Ardelyx Shares Are Rising

Why Ardelyx Shares Are Rising

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company’s second level of appeal of the Complete Response Letter for XPHOZAH.

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ:ARDX) second level of appeal of the Complete Response Letter (CRL) for Xphozah. Ardelyx is seeking approval for Xphozah to control serum phosphorus in adult patients with chronic kidney disease (CKD) on…

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Kyowa Kirin, Ardelyx Amend Tenapanor Pact In Cardiorenal Disorders

Ardelyx Inc (NASDAQ: ARDX) has

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Ardelyx Inc (NASDAQ:ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that will launch in April and whose commercial…

Get all your
news in one place.

100's of premium titles.
One news app.

Ardelyx: Q4 Earnings Insights

Ardelyx (NASDAQ:ARDX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Ardelyx missed estimated earnings by 3.33%, reporting an EPS of $-0.31 versus an estimate of $-0.3.

Earnings Preview: Ardelyx

Ardelyx (NASDAQ:ARDX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Ardelyx will report an earnings per share (EPS) of $-0.30.

Earnings Outlook For Ardelyx

Ardelyx (NASDAQ:ARDX) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Ardelyx will report an earnings per share (EPS) of $-0.30.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Cantor Fitzgerald

Canaccord Genuity

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,466 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play